

Listing of Claims:

Claim 1 (current amended) The method of improving FMF control, in humans, treating Familian Mediterranean Fever (FMF) in a patient suffering only from FMF, which includes consists of orally administering, on an average daily basis, for at least 5 months, between 5 and 15 milligrams of LTRA leukotriene receptor antagonist (LTRA) selected from the group consisting of 4-5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl-3-methoxy-N-o- tonylsulfanylbenzamide and montelukant sodium to [[a]] said patient suffering from FMF, for treatment only of FMF and continuing said administration at said milligram level, and said average daily basis level as long as the FMF symptoms continue.

Claim 2 (cancelled)

Claim 3 (currently amended) The method of claim [[2]] 1 wherein said LTRA is administrated orally in tablet form, wherein about 10 milligrams of said LTRA is administered, on a daily basis, and wherein said LTRA consists of ZAFIRLUCAST tablets.

Claim 4 (currency amended) The Method of claim 1
wherein said LTRA is administered orally in tablet form,
wherein about 10 milligrams of said LTRA is administered, on
a daily basis, and wherein said LTRA consists of SINGULAIR
tablets.

Claim 5 (previously presented) The method of
claim 1 wherein said patient is between 9 and 72 years old.

Claim 6 (cancelled)

Claim 7 (cancelled)